The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

10 December 2025

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Placing of £1,000,000

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical stage company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that it has successfully raised £1,000,000 by way of an oversubscribed placing of 11,111,112 new ordinary shares of no par value each in the Company ("Placing Shares") at a price of 9 pence per share (the "Issue Price") (the "Placing"). The Placing Shares each have an attaching grant of warrants ("Warrants") on a one for two basis, exercisable at a price of 15 pence per ordinary share, and expiring on 31 December 2026.

The Placing Shares will represent approximately 21.76% of the Company's enlarged issued share capital following the Placing. The Issue Price represents a discount of approximately 18.18 per cent. to the closing mid-market price of 9 pence per ordinary share on 09 December 2025.

The Placing was undertaken by the Company's broker, SP Angel Corporate Finance LLP.

The Company values its retail shareholder base and believes that it is appropriate to provide existing retail and other shareholders the opportunity to purchase shares at the Issue Price.  The Company intends to carry out a separate retail offer to raise further gross proceeds of up to £100,000 via the BookBuild Platform (the "Retail Offer"). A further announcement will be made shortly regarding the Retail Offer and its terms.

Highlights of the Placing:

-      Completion of Placing raising £1,000,000 through the issue of 11,111,112 Placing Shares at 9 pence per share

-      The net proceeds of the Placing will allow the Company to progress its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma. Specifically, funds will be used for:

o  Sterilisation and lot release of GMP of ChemoSeed

o  QP, quality and audit fees

o  Clinical trial costs - ongoing fees, dose escalation seeking efficacy signal in recurrent patients

o  Ongoing operational costs

-      A separate retail offer to existing holders will be launched shortly

CRISM Executive Chairman, Andrew Webb, said: "We are delighted by the support of new and existing shareholders in this oversubscribed Placing, which will enable the Company to progress into patient dosing in its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma and to reach the important inflexion point of establishing an efficacy signal in patients with recurrent disease, subject to patient recruitment. We look forward to first patient dosing in Q1 2026."

Rationale for the Placing

The Placing will enable the Company to progress its Phase 2 open-label clinical trial, with first patients expected to be dosed in Q1 2026. The open label trial design allows for ongoing safety and efficacy monitoring.

Directors' Participation and Related Party Transactions

The Directors of the Company have participated in the Placing, details of which are in the table below:

The participation of Andrew Webb, Chris McConville and Gerry Beaney in the Placing (including the issue of the Warrants referred to below) constitutes related party transactions for the purposes of Rule 13 of the AIM Rules for Companies. As all of the Directors are participating in the Placing, there is no independent director for the purpose of the related party transaction as stipulated by the AIM Rules for Companies.

The Company's nominated adviser, SP Angel Corporate Finance LLP, considers that the Directors' participation in, and the terms of, the Placing is fair and reasonable in so far as CRISM's shareholders are concerned.

Warrants

The Company will issue participants of the Placing with one Warrant for every two Placing Shares. As a result, 5,555,551 Warrants will be issued to the placees. Each Warrant will provide the holder with the right to one new ordinary share on its exercise. The Warrants will be exercisable at a price of 15 pence until 31 December 2026.

Andrew Webb, Chris McConville and Gerry Beaney, have been issued with 458,333, 41,666 and 55,555 Warrants respectively, as a result of their participation in the Placing.

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the Placing Shares ("Admission"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 15 December 2025, or such later date as may be agreed between the Company and SP Angel. The Placing Shares will rank pari passu with the Company's existing ordinary shares.

Following the issue of the Placing Shares, the total issued share capital of the Company will consist of 51,072,934 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 51,072,934 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

Enquiries:

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed™ in patients with surgically resectable glioblastoma in Q1 2026.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

Dealings by Persons Discharging Managerial Responsibilities